Q-omics provides the consensus-scored MARK2P9 profile across patient tissues and cancer cell-line models. MARK2P9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MARK2P9 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, MARK2P9 RNA expression shows 15,953 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, and UVM as cancer lineages where MARK2P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARK2P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARK2P9 survival associations across molecular data types. MARK2P9 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARK2P9 RNA expression–survival associations across cancer types. High MARK2P9 expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, STAD, CHOL and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MARK2P9 RNA expression.
This table summarizes MARK2P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MARK2P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARK2P9 shows lower tumor expression in BRCA and higher tumor expression in HNSC, UCEC, STAD, COAD and LIHC. The HNSC box plot shows higher MARK2P9 RNA expression in tumor versus normal tissue (log2 FC = +0.114, t-test p < 0.001).
This table shows molecular features associated with MARK2P9 in patient tissues and cancer cell lines. In patient samples, MARK2P9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
